• Eli Lilly and Company reported past first-quarter 2026 results with sales of US$19.80 billion and net income of US$7.40 billion, sharply higher than a year earlier, driven largely by its incretin portfolio.
• The quarter also saw FDA approval and launch of Foundayo, Eli Lilly’s oral GLP‑1 weight-loss pill, alongside an FDA proposal to limit compounded GLP‑1 copies, which together could reshape the competitive landscape for its obesity and diabetes franchise.
• We’ll now examine how Eli Lilly’s Q1 earnings beat and Foundayo launch affect the existing investment narrative around its GLP‑1 portfolio.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Eli Lilly Investment Narrative Recap

To own Eli Lilly today, you need to believe its incretin franchise can keep driving earnings while the company actively broadens beyond a few blockbuster GLP‑1 drugs. Q1’s earnings beat and the Foundayo launch reinforce that story in the near term, and the FDA’s proposed clampdown on compounded GLP‑1 copies supports the key short term catalyst: sustained, branded demand. The biggest risk remains concentration in a small number of high profile obesity and diabetes products.

Among recent updates, Lilly’s new AI driven gene editing collaboration with Profluent stands out as most relevant to the current narrative. While GLP‑1s powered Q1 results, deals like Profluent’s up to US$2,250 million recombinase partnership speak to a parallel catalyst: building future growth options outside obesity, which could matter more if pricing pressure or competition eventually bite into incretin profits.

Yet beneath the strong quarter, investors should still pay close attention to how tightening drug price reforms could eventually reshape Lilly’s GLP‑1 economics and...

Eli Lilly's narrative projects $106.9 billion revenue and $42.9 billion earnings by 2029. This requires 17.9% yearly revenue growth and about a $22.3 billion earnings increase from $20.6 billion today.

Uncover how Eli Lilly's forecasts yield a $1209 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming roughly US$84 billion of revenue and US$31.8 billion of earnings by 2028, so if you worry about government pricing pressure on obesity drugs more than about volume growth, their more pessimistic view might resonate and could shift again as the latest GLP 1 results and policy moves are fully reflected.

Explore 24 other fair value estimates on Eli Lilly - why the stock might be worth 8% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Eli Lilly research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Eli Lilly research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Eli Lilly's overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.